Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects for whom the investigator believes their parents/guardians can and will comply with the requirements of the protocol.~* Male or female between 12 and 14 months of age at the time of first vaccination.~* Written informed consent obtained from the parent/guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Have previously received 3 doses of 7-valent pneumococcal conjugate vaccine within the first year of life.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol from 30 days prior to vaccination until 42 days after vaccination, except for influenza vaccine.~* Previous vaccination against measles, mumps, rubella and/or varicella.~* Previous vaccination against hepatitis A or receipt of a fourth dose of pneumococcal conjugate vaccine.~* History of measles, mumps, rubella and/or varicella/zoster diseases.~* Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the study.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination, including human immunodeficiency virus infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures. Uncomplicated febrile convulsions are not an exclusion criterion.~* Residence in the same household as the following persons:~  * New-born infants (0-4 weeks of age).~ * Pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox.~ * Pregnant women at or beyond 28 weeks gestation regardless of varicella vaccination status or varicella disease history.~ * Persons with known immunodeficiency.~* Acute disease at the time of enrolment. All vaccines can be administered to persons with a minor illness.~* Administration of polyclonal immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.~* Contra-indications to commercially available vaccines used in this study (Havrix®, Prevnar®, ProQuad®).

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 14 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
- Group B (Type: EXPERIMENTAL): Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
- Group C (Type: ACTIVE_COMPARATOR): Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180

Based on this trial design, predict the completion outcome and termination type (if applicable).